A Study to Compare the Frequency of Constipation Symptoms With Tapentadol Immediate Release (IR) Treatment Versus Oxycodone IR Treatment in Patients With End-stage Joint Disease

NCT ID: NCT00784277

Last Updated: 2012-02-13

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 597 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2008-10-31
• Study Completion Date: 2009-07-31

Brief Summary

The purpose of this study is to compare bowel function/constipation that occurs during tapentadol treatment with that occuring during oxycodone treatment, as measured by the frequency of spontaneous bowel movements per week. The frequency of spontaneous bowel movements will be determined from a Bowel Function Patient Diary completed by the enrolled sujbects.

Detailed Description

Chronic pain from end-stage degenerative joint disease is often moderate to severe in intensity and results in a relatively constant level of pain requiring continuous pain relief medication. Despite available pain relief medications, 60% to 80% of subjects suffering from chronic pain are currently inadequately treated. Opioid pain medications are central to the effective treatment of moderate to severe pain. However, opioid therapy is frequently complicated by side effects. Constipation is one of the most commonly reported side effects and most debilitating. An opioid medication that provides pain relief with a reduced incidence of constipation symptoms would improve the capability of subjects to stay on medication to achieve the long-term relief they need. This is a randomized, double-blind, placebo- and active-controlled, parallel-arm, multicenter study with 4 treatment groups of subjects who have moderate to severe chronic pain from end-stage degenerative joint disease of the hip or knee and who are candidates for primary total or partial joint replacement. The study consists of 3 periods: a pretreatment period (a 14-day screening for study eligibility and a 7-day washout of any previously taken opioid medication), a double-blind treatment period (a 14-day IR treatment phase followed by a 28-day ER treatment phase), and a follow-up period (1 study-site visit within 4 days after the last dose of study drug is taken and 1 telephone contact within 10 to 14 days after the last dose of study drug is taken). On Day 1 of the IR treatment phase, patients will be randomly assigned to 1 of 4 possible treatment groups to receive 50 mg CG5503 IR, 75 mg CG5503 IR, 10 mg oxycodone IR, or placebo daily every 4 to 6 hours. At the beginning of the ER treatment phase, patients' study drugs will be transitioned to the ER form (by conversion from the IR to approximate equivalent total daily doses of the ER form) of their randomly assigned study drug of tapentadol ER, oxycodone CR, or placebo. The ER study drugs will be taken every 12 hours b.i.d. Dosages will be adjustable, with the study site personnel oversight, to ensure adequate pain relief is provided. Beginning with the washout period, patients will be given hand-held computer diaries in which to record their pain intensity, pain relief, bowel movement information, and answer questions on any nausea or vomiting that may occur. In addition, patients will write down the times and dosages of all medications they take during the study in a medication diary. Safety and tolerability will be assessed using physical examination, monitoring of adverse events, clinical and laboratory measures, and 12 lead ECG results. The first study hypothesis is that both tapentadol IR dosages are more effective than placebo in relieving pain based on the SPID score recorded by the patients over the first 5 days of the study. The second study hypothesis is that the Bowel Function Patient Diary results for both tapentadol IR dosages demonstrate improved tolerability compared to oxycodone IR 10 mg, based on the number of spontaneous bowel movements per week over the first 2 weeks of the study. In the IR treatment phase, each patient will take CG5503 IR 50 mg, CG5503 IR 75 mg, oxycodone IR 10 mg, or placebo orally every 4 to 6 hours for 14 days. In the ER treatment phase, dosages of the IR treatment groups will be converted to approximately equivalent dosages of the ER form of the assigned study drug: tapentadol ER, oxycodone CR, or placebo. Dosages may range from 100 to 500 mg/day of tapentadol ER and 20 to 60 mg/day of oxycodone CR taken orally 2x daily for 28 days.

Conditions

Joint Diseases; Arthritis; Osteoarthritis

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

001

Tapentadol IR (CG5503) 50mg for 14 days

Group Type: EXPERIMENTAL

Tapentadol IR (CG5503)

Intervention Type: DRUG

50mg for 14 days

002

Tapentadol IR (CG5503) 75mg for 14 days

Group Type: EXPERIMENTAL

Tapentadol IR (CG5503)

Intervention Type: DRUG

75mg for 14 days

003

oxycodone IR 10mg for 14 days

Group Type: ACTIVE_COMPARATOR

oxycodone IR

Intervention Type: DRUG

10mg for 14 days

004

placebo 1 capsule for 14 days

Group Type: PLACEBO_COMPARATOR

placebo

Intervention Type: DRUG

1 capsule for 14 days

005

Tapentadol ER (CG5503) flexible dose tablets and capsules 2 x a day for 28 days (100-500mg/day)

Group Type: EXPERIMENTAL

Tapentadol ER (CG5503)

Intervention Type: DRUG

flexible dose tablets and capsules 2 x a day for 28 days (100-500mg/day)

006

oxycodone CR flexible dose tablets and capsules 2 x a day for 28 days (20-60mg/day)

Group Type: ACTIVE_COMPARATOR

oxycodone CR

Intervention Type: DRUG

flexible dose tablets and capsules 2 x a day for 28 days (20-60mg/day)

007

placebo Tablets and capsules 2 x a day for 28 days

Group Type: PLACEBO_COMPARATOR

placebo

Intervention Type: DRUG

Tablets and capsules 2 x a day for 28 days

Interventions

oxycodone CR

flexible dose tablets and capsules 2 x a day for 28 days (20-60mg/day)

Intervention Type: DRUG

oxycodone IR

10mg for 14 days

Intervention Type: DRUG

Tapentadol ER (CG5503)

flexible dose tablets and capsules 2 x a day for 28 days (100-500mg/day)

Intervention Type: DRUG

Tapentadol IR (CG5503)

50mg for 14 days

Intervention Type: DRUG

Tapentadol IR (CG5503)

75mg for 14 days

Intervention Type: DRUG

placebo

1 capsule for 14 days

Intervention Type: DRUG

placebo

Tablets and capsules 2 x a day for 28 days

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• A clinical diagnosis of osteoarthritis of the hip or knee
• End-stage degenerative joint disease
• Eligibility for primary unilateral total or partial joint replacement surgery
• Pain level moderate to severe and at such a level as to require daily doses of an opioid analgesic medication

Exclusion Criteria

• Has a life-long history of seizure disorder or epilepsy
• Had any of the following within the preceding 1 year: mild or moderate traumatic brain injury, stroke, transient ischemic attack, or brain neoplasm
• Had a severe traumatic brain injury within 15 years of screening (consisting of one or more of the following: brain contusion, intracranial hematoma, either unconsciousness or post traumatic amnesia lasting for more than 24 hours)
• Joint pain not associated with gout, fibromyalgia, rheumatoid arthritis, other autoimmune disease
• History of alcohol or drug abuse
• chronic hepatitis B and C or HIV, active hepatitis B and C within 3 months
• Severely impaired renal function or moderately to severely impaired hepatic function
• History of cancer within past 2 years

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Grünenthal GmbH

INDUSTRY

Sponsor Role: collaborator

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

INDUSTRY

Sponsor Role: lead

Responsible Party

Johnson & Johnson Pharmaceutical Research and Development, L.L.C.

Principal Investigators

Johnson & Johnson Pharmaceutical Research & Development, L.L. C. Clinical Trial

Role: STUDY_DIRECTOR

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

References

Etropolski M, Kelly K, Okamoto A, Rauschkolb C. Comparable efficacy and superior gastrointestinal tolerability (nausea, vomiting, constipation) of tapentadol compared with oxycodone hydrochloride. Adv Ther. 2011 May;28(5):401-17. doi: 10.1007/s12325-011-0018-0. Epub 2011 Apr 13.

Reference Type: DERIVED

PMID: 21494892 (View on PubMed)

Other Identifiers

KF5503/41

Identifier Type: -

Identifier Source: secondary_id

CR014326

Identifier Type: -

Identifier Source: org_study_id